A Phase 1/2 Study of KB304, a Replication-Defective, Non-Integrating Vector Expressing Human Type III Collagen (COL3) and Tropoelastin for the Treatment of Wrinkles
Latest Information Update: 21 May 2025
At a glance
- Drugs JN 304 (Primary) ; Sodium chloride
- Indications Skin wrinkles
- Focus Therapeutic Use
- Acronyms Pearl-2
- Sponsors Krystal Biotech
Most Recent Events
- 13 May 2025 Planned primary completion date changed from 1 May 2025 to 1 Jul 2025.
- 13 May 2025 Status changed from recruiting to active, no longer recruiting.
- 06 May 2025 According to a Krystal Biotech media release, In February, Jeune Aesthetics completed enrollment in PEARL-2, an ongoing, randomized and placebo-controlled Phase 1 study evaluating KB304 for the treatment of wrinkles.